0
Skip to Content
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Folder: GET INVOLVED
Folder: RESEARCH
Folder: NEED HELP?
BLOG
MERCH
DONATE
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
West, Oregon Julia Travagline 11/20/24 West, Oregon Julia Travagline 11/20/24

Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia

Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia

Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR

Read More
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Midwest, Missouri Julia Travagline 11/20/24 Midwest, Missouri Julia Travagline 11/20/24

Cooperative mutagenesis driving pediatric pre-B cell leukemia

Cooperative mutagenesis driving pediatric pre-B cell leukemia

Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO

Read More
Dietary valine modulation to enhance therapies for high-risk T-ALL
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Dietary valine modulation to enhance therapies for high-risk T-ALL

Dietary valine modulation to enhance therapies for high-risk T-ALL

Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX

Read More
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Northeast, Mas Julia Travagline 11/20/24 Northeast, Mas Julia Travagline 11/20/24

Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients

Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients

Dr. Kristopher Sarosiek, Ph.D. – President and Fellows of Harvard College, Harvard T. H. Chan School of Public Health, Boston, MA

Read More
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Midwest, Michigan Julia Travagline 11/20/24 Midwest, Michigan Julia Travagline 11/20/24

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI

Read More
Validating PRL2 as a New Therapeutic Target in T-ALL
Midwest, Illinois Julia Travagline 11/20/24 Midwest, Illinois Julia Travagline 11/20/24

Validating PRL2 as a New Therapeutic Target in T-ALL

Validating PRL2 as a New Therapeutic Target in T-ALL

Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Read More
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
International, Israel Julia Travagline 11/20/24 International, Israel Julia Travagline 11/20/24

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel

Read More
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Northeast, New York Julia Travagline 11/20/24 Northeast, New York Julia Travagline 11/20/24

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark